|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.62/-0.84
|
企業價值
7.67M
|
資產負債 |
每股賬面淨值
0.15
|
現金流量 |
現金流量率
--
|
損益表 |
收益
895.48K
|
每股收益
0.04
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/11/15 20:46 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. |